Differentiated Thyroid Carcinoma Clinical Trial
Official title:
The Effectiveness and Safety of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma: a Phase 2 Trial.
This is a non-randomized, phase II, open label study of Apatinib Mesylate in patients with with locally advanced or metastatic differentiated thyroid carcinoma (DTC). The purpose of this study is to evaluate the efficacy and safety of apatinib in patients with locally advanced or metastatic differentiated thyroid carcinoma.
At present, multiple anti-angiogenesis drugs for thyroid cancer of clinical research are ongoing worldwide, and most of which achieved fairly good therapeutic effect. To date, sorafenib has been approved for the treatment of radioactive iodine refractory DTC. Apatinib is a highly selective VEGFR2 inhibitor that reduces the angiogenesis of tumor efficiently, and had been proven to be effective in many solid tumors. In this study, the investigators aim to further explore the efficacy and safety of apatinib in locally advanced or metastatic differentiated thyroid carcinoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00251316 -
Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT06359847 -
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT01704586 -
I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer
|
N/A | |
| Active, not recruiting |
NCT03776123 -
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
|
||
| Not yet recruiting |
NCT04916262 -
Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer
|
||
| Active, not recruiting |
NCT04970134 -
Spanish Study for Molecular Characterization of Thyroid Carcinoma
|
||
| Completed |
NCT00439127 -
OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation
|
N/A | |
| Recruiting |
NCT03845647 -
Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.
|
N/A |